Today, Prescription Justice announced that it has published a Congressional report card on drug prices. This first of its kind Congressional report card on drug prices can help voters and political organizations determine who they want to support in upcoming elections.
The Prescription Justice Board of Directors stands with AARP and Families USA in support of the administration’s Safe Importation Action Plan but strongly urges Congress and the administration to quickly enact more impactful reforms to address the nation’s prescription drug price crisis.
As a reminder, Prescription Justice brought 24 organizations together in support of the Affordable and Safe Prescription Drug Importation Act.
The pharmaceutical industry often defends shameful price gouging of consumers by arguing that their high profits fund the research and development of tomorrow’s new miracle cures. There is robust debate about the degree to which lowering drug prices would hurt pharmaceutical innovation. The current system holds consumers and governments hostage to pharmaceutical company business models in a manner that is inherently unethical. Think of the cancer patient who has to shell out $30,000 in co-insurance to live, and if not, then die.
The concept and practice of “delinkage,” in which the invention of new medicines is delinked from high drug prices transcends this old debate and envisions a brighter more humane future…one with robust pharmaceutical innovation.